We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




License To Market Leukemia Service in Canada

By HospiMedica staff writers
Posted on 21 Aug 2007
Warnex (Laval, Canada) announced an exclusive license with Ipsogen SAS (Marseille, France) to market a service in Canada for the molecular diagnosis and classification of a group of leukemias.

The service is based on the analysis of variations in the JAK2 gene, to which Ipsogen has exclusive worldwide intellectual property rights. More...
A dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2A is present in a high proportion of patients with myeloproliferative disorders (MPD) such as polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.

The president and CEO of Ipsogen, Vincent Fert, said, The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs.

Mark Busgang, president and CEO of Warnex commented, In addition to expanding our service offering in medical testing, this license provides Warnex with the exclusivity for JAK2 clinical testing performed in Canada, thus significantly enhancing our market position. Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders.


Related Links:
Warnex
Ipsogen SAS

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gastrointestinal Panel
Xpert® GI Panel
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.